Prolactinomas are the most prevalent pituitary secretory adenomas, accounting for roughly 40% of all pituitary adenomas.1 Although most prolactinoma symptoms and signs are related to mass effect or hypogonadism, reduced bone density, weight gain, impaired lipid and metabolic profile can also be observed in patients.2,3

Prolactin modulates mediators in glucose and lipid metabolism, increases insulin release and inhibits fat storage.4 Although these effects are considered to enhance the risk of nonalcoholic fatty liver disease (NAFLD) in prolactinoma patients, the association between prolactinoma and NAFLD has not been extensively explored in the literature.

Hyperprolactinemia is also accelerate bone resorption due to hypogonadism.5 Skeletal muscle also possesses a receptor for prolactin,6 However, direct influence of prolactin on muscle are not extensively discussed in the literature.

In this study, we searched for association between NAFLD, hepatic fibrosis, and osteosarcopenia in people with active prolactinoma.